Press Releases

On 27 July 2023, on the eve of the highly anticipated Chengdu FISU World University Games, the Minister of Health Indonesia Budi Gunadi Sadikin accompanied Indonesian President Joko Widodo on a visit to China. The Indonesia-China Healthcare and Biotech Investment Forum, co-hosted by the Embassy of the Republic of Indonesia in China and the Indonesian Chamber of Commerce and Industry Bilateral Committee for China (KIKT), and supported by Legend Capital and Indonesia Chamber of Commerce in Chin

J INTS BIO announced the successful dosing of the first patient in its global multi-center Phase 1/2 clinical study of 'JIN-A02' on 31st July at Severance Hospital, Seoul, Korea. More clinical sites will follow suit, including seven more hospitals in Korea (National Cancer Center, Chungbuk National University Hospital, Samsung Seoul Hospital, Seoul National University Hospital, Seoul St. Mary's Hospital, St. Vincent Hospital, Asan Medical Center), two in the United State

Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of biopharmaceutical drugs, and RheaVita, a pioneer and supplier of continuous freeze-drying technology for biopharmaceutical products, today announced their collaboration to pave the path of the novel technology for drug product development of biologics, in particular novel modalities. RheaVita's patented continuous freeze-drying technology integrates all

Nanjing Leads Biolabs Co., Ltd. announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investigational New Drug (IND) applications for LBL-034, an anti-GPRC5D/CD3 bispecific antibody invented by Leads Biolabs with global intellectual property rights, for the treatment of relapsed/refractory multiple myeloma. Currently, no GPRC5D-targeting antibody has been approved for marketing. This

Natera, Inc., a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive trial platform evaluating the utility of the Signatera molecular residual disease (MRD) test in patients with stage II-IV resectable colorectal cancer (CRC). CIRCULATE-Japan also includes the o

Hi-Tech Pharmaceuticals, a leading manufacturer of cutting-edge dietary supplements and weight management supplements, is proud to announce the launch of its latest product, Berberine Cyclosome®. This groundbreaking supplement provides a natural and effective solution for blood sugar metabolism support and healthy weight management.* Hi-Tech Pharmaceuticals is a leader in phellodendron and berberine research with its Nexrutine® series of berberine extracts, which have over two decades

Community research provider EmVenio Research today announced a partnership with TrialHub, a data intelligence platform that delivers real-time patient insights and empowers EmVenio to conduct a wider range of clinical trials for new life-saving treatments. Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed to support pharmaceutical sponsors and clinical research organizations' parti

PromoCell, a leading manufacturer of cell culture products, announced the launch of PromoExQ MSC Growth Medium XF, a serum- and xeno-free cell culture medium designed for GMP compliant maintenance and long-term expansion of mesenchymal stem cells (MSCs) for cell therapy manufacturing applications. PromoExQ MSC Growth Medium XF enables the long-term expansion of a variety of MSC types, including MSCs from the bone marrow, umbilical cord matrix, and adipose tissue, and ensures their c

MyoPax has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its regenerative cell therapy in Exstrophy-Epispadias Complex (EEC). MyoPax aims to repair the congenital muscle defect associated with EEC using its cutting-edge highly regenerative muscle stem cell product. EEC is a severe newborn condition within the uro-rectal congenital malformation spectrum impacting continence, sexual and renal function. MyoPax's cell therapy uses patient-sp

PHASE Scientific Americas, a fast-growing biotechnology company actively developing innovative solutions to revolutionize diagnostics in healthcare announces that their PHASE Scientific Medical Laboratory (PHASE Lab) has been certified by Clinical Laboratory Improvement Amendments (CLIA) and issued licensure by the California Department of Public Health (CDPH) to perform moderate and high-complexity testing. CLIA certification is based on a Quality Management System framework that e